28 Analysts Have This To Say About Regeneron Pharmaceuticals
28 Analysts Have This To Say About Regeneron Pharmaceuticals
28 位分析師對再生元製藥公司的看法
The standing of Regeneron Pharmaceuticals...Regeneron Pharmaceuticals (NASDAQ:REGN) underwent analysis by 28 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
再生元製藥公司（納斯達克:REGN）在上個季度接受了28名分析師的分析，顯示出從看好到看淡的不同觀點。
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近的評級概況，突出了過去30天內情緒的變化，並將其與之前的月份進行了比較。
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $1156.14, accompanied by a high estimate of $1300.00 and a low estimate of $895.00. Experiencing a 3.64% decline, the current average is now lower than the previous average price target of $1199.85.
分析師最近評價了再生元製藥公司，並提供了12個月的價格目標。平均目標爲1156.14美元，最高估計爲1300.00美元，最低估計爲895.00美元。經歷了3.64%的下降，當前平均值目前低於之前的平均價格目標1199.85美元。
Decoding Analyst Ratings: A Detailed Look
Decoding Analyst Ratings: A Detailed Look
The standing of Regeneron Pharmaceuticals...
通過對最近...
登入免費觀看全文
登入/註冊
資訊熱榜
更新時間